“Global Protein Expression market set to grow to $3.2bn by 2024” says Visiongain report

24 October 2019
Pharma

Visiongain has launched a new pharma report Global Protein Expression Market Report: Cell-free Expression System, Prokaryotic/Bacterial Expression System, Yeast Cell Expression Systems, Algal-based Expression Systems, Insect Cell Expression Systems, Mammalian Cell Expression Systems, Reagents, Expression Vectors, Competent Cells, Instruments, Services, Therapeutic Applications, Industrial Application, Research Application, Pharmaceutical and Biotechnology Companies, Academic Research Institutes, Contract Research Organizations (CROs).

The global protein expression market is estimated at $1.8bn in 2018. Visiongain estimated that the prokaryotic expression system accounted for 40.0% of the global protein expression market.

The lead analyst of the report commented "Recombinant proteins will continue to be essential reagents for drug discovery projects in the future and that technological developments will emerge to match changes in demand or to keep in step with advances in other application areas. Another great opportunity for future growth in the protein expression market is provided by emerging countries, especially China and India. Their markets are growing at a faster rate than that of the developed Western markets.

The demand for expertise in recombinant protein expression development is another opportunity for the market, and this will allow smaller niche companies to compete with the large multinational CROs, resulting in more companies entering the market and more products and services being offered."

Leading companies featured in the report include Agilent Technologies, Bio-Rad Technologies, EMD Milipore, New England Biolabs, Inc., Oxford Expression Technologies, Ltd., Promega Corporation, Qiagen NV, Takara Bio, Inc., Thermo Fisher Scientific, Inc. and other companies.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Clinical Trial Supplies Market Report 2021-2031

Deviating from protocols raises the danger of missing or delaying data collection from current investigations. This highlights the growing importance of digital medicine, which is being aided by advancements in cloud, mobile, and IoT technology.

11 October 2021

Read

Visiongain Publishes Drug Discovery Informatics Market Report 2021-2031

High performance HPC and supercomputing technology have evolved substantially in China in the last decades, leading to extraordinary accomplishments. HPC-based and combined pharmaceutical chemical and computational biology computational discovery and design has become a significant technique in drug research and development and is sponsored financially by the Chinese government.

07 October 2021

Read

Visiongain Publishes Pharma Wholesale and Distribution Market Report 2021-2031

Many health-care organizations are seeing organic growth at levels that their supply networks were never designed to handle. Others are frantically attempting to integrate diverse technology and procedures as part of a consolidation effort.

06 October 2021

Read

Visiongain Publishes Meningococcal Vaccines Market Report 2021-2031

Rise in prevalence of meningitis, increasing initiatives by government and regulatory authorities coupled strong funding support from non-profit organizations is expected to drive the global meningococcal vaccines market

05 October 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever